HIV treatment support for people with gaps in care
Part of Immune system & allergy, Infections clinical trials.
This study is for people with HIV who have had a gap in care (missed an appointment or had a detectable viral load). It tests a program to help you stay on your dolutegravir-based HIV medication and keep your viral load undetectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HIV and are taking a dolutegravir-based medication as your first HIV treatment.
- In the past year, you missed a clinic visit by more than 28 days OR had a viral load of 50 or higher.
- You are willing to keep your contact information updated for the study.
- You do not have active tuberculosis or epilepsy that requires clinic visits, and you are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers extra support for people who are starting or restarting HIV medication. It tests whether giving people a choice in their treatment support helps them stay healthy.
This study is testing a program to help people with HIV stick with their medication. It looks at how well doctors and patients work together to make treatment decisions and improve health outcomes.
This study lets people who finished an earlier HIV treatment study keep getting the same medicine while a new trial is set up. It helps ensure you don't have a gap in your treatment.
This study tests a program that helps people with HIV manage depression and stick to their treatment. It's for adults in Cape Town, South Africa, who have a detectable HIV viral load or may have one, and who show signs of depression.
This study tests a special pill that has a sensor inside, which sends information to your doctor or care team to help you remember to take your HIV medication. It is for people who sometimes miss doses and want extra support.
This trial tests different ways to manage “virologic failure,” meaning HIV viral load stays high while taking TLD (a common HIV medicine combination). It may help people better control the virus and improve treatment results, especially in parts of sub-Saharan Africa.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.